Search Result

Results for "

PET+imaging

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amino Acid Derivatives (1) Amyloid-β (1) Apoptosis (2) Biochemical Assay Reagents (17) Bombesin Receptor (1) Cannabinoid Receptor (2) Carbonic Anhydrase (2) CXCR (3) Cytochrome P450 (2) DNA/RNA Synthesis (1) Drug Derivative (4) Drug Intermediate (2) EGFR (3) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) FAAH (1) FAP (4) Fluorescent Dye (2) Formyl Peptide Receptor (FPR) (1) G-quadruplex (1) Galectin (1) GLUT (1) Glycine Receptor (GlyR) (1) Glycoprotein VI (1) Histone Demethylase (1) hnRNP (1) HSP (1) Integrin (2) Interleukin Related (2) Isotope-Labeled Compounds (2) Melanocortin Receptor (2) mGluR (1) Mitochondrial Metabolism (1) MMP (1) MOFs (1) Neurokinin Receptor (1) Neurotensin Receptor (1) P2Y Receptor (1) PARP (1) PD-1/PD-L1 (1) PSMA (4) Radionuclide-Drug Conjugates (RDCs) (31) Reference Standards (1) RIP kinase (1) Somatostatin Receptor (4) Src (1) Tau Protein (2) TREM receptor (2) TROP2 (1) VISTA (1) α-synuclein (1)
By Research Areas:	Cancer (62) Cardiovascular Disease (5) Endocrinology (1) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (17)
Click Chemistry:	Tetrazine (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10136

IA9 2 Publications Verification human TREM-2 182-190	TREM receptor	Inflammation/Immunology
IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-W087028

NOTA-NHS ester	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents CXCR	Cancer
NOTA-NHS ester is a chelating agent. NOTA-NHS ester can be coupled with T140 (HY-P4810) to produce NOTA-T140. NOTA-T140 can be radiolabeled with Al[ ¹⁸F]. The uptake of Al[ ¹⁸F]NOTA-T140 in tumors is correlated with the expression level of CXCR4. Al[ ¹⁸F]NOTA-T140 can be used in tumor PET imaging studies. NOTA-NHS ester can be used for fluorescent labeling .

HY-134797

p-SCN-Bn-deferoxamine 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
P-SCN-Bn-deferoxamine is a bifunctional chelating agent that can link radioactive metal nuclides (such as Zr-89) and biological targeting molecules (such as antibodies). P-SCN-Bn-deferoxamine can be used for the research of immune PET imaging .

HY-120947

AV-105	Drug Intermediate	Neurological Disease
AV-105 is a Florbetapir ( ¹⁸F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize ¹⁸F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .

HY-W087027

Maleimide-NOTA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin	Cancer
Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ ⁶⁸Ga]Ac-CG6 formed by the conjugation of ⁶⁸Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-134418

NOTA	Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-141637

2-Deoxy-2-fluoro-D-glucose 2 Publications Verification 2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose	Biochemical Assay Reagents	Cancer
2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-W250574

NOTA-bis(tBu)ester NOTA-bis(t-Butyl ester)	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Drug Derivative	Cancer
NOTA-bis (tBu) ester is a derivative of NOTA (HY-134418). NOTA-bis (tBu) ester is radiolabeled with ⁶⁸Ga to form ZD2-( ⁶⁸Ga-NOTA) after conjugation with ZD2. ZD2-( ⁶⁸Ga-NOTA) can be used for PET imaging studies of pancreatic cancer .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives Biochemical Assay Reagents	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-P2336A

CCZ01048 TFA 3 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P10136A

IA9 TFA 2 Publications Verification human TREM-2 182-190 TFA	TREM receptor	Inflammation/Immunology
IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-156991

NODAGA-NHS NODA-GA-NHS ester	EGFR Radionuclide-Drug Conjugates (RDCs)	Cancer
NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate ⁶⁴Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [ ⁶⁴Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma .

HY-137557

Florzolotau APN1607; PM-PBB3	Tau Protein	Neurological Disease
Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .

HY-155483

PSMA-BCH NOTA-PSMA	Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools .

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents	Cancer
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-100275

MK-3328	Amyloid-β	Neurological Disease
MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM. MK-3328 is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging .

HY-163574

TDP-43 ligand-1 1 Publications Verification	hnRNP	Neurological Disease
TDP-43 ligand-1 is a specific ligand for TDP43, and its K_i value for binding to TDP-43 protein aggregates is 78 nM. TDP-43 ligand-1 can be used in the research of PET imaging probes for TDP-43 proteinopathies.

HY-159768A

DOTAGA.Glu.(FAPi)2	Radionuclide-Drug Conjugates (RDCs) FAP	Neurological Disease Cancer
DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- ⁶⁸, lutetium- ¹⁷⁷ or terbium- ¹⁶¹, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .

HY-12761

A-836339	Cannabinoid Receptor	Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H₂O₂). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc .

HY-177459

DOTA-2P(FAPI)2	FAP	Cancer
DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-172205

CHL2310	Cytochrome P450	Cancer
CHL2310 is the inhibitor for CYP46A1 with an IC₅₀ of 0.11 nM, and a K_d of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive ¹⁸F .

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAPPET imaging and radionuclide therapy of cancers research .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents	Cancer
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

HY-175730

CB2R ligand-1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology Cancer
CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with K_i of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-134418R

NOTA (Standard)	Radionuclide-Drug Conjugates (RDCs) Reference Standards	Cardiovascular Disease Cancer
NOTA (Standard) is the analytical standard of NOTA. This product is intended for research and analytical applications. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-180447

Tz-Ph-PEG4-NH-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

HY-169868

NOTA-FAPI-52	Biochemical Assay Reagents	Cancer
NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .

HY-174977

P2Y12R ligand-1	P2Y Receptor	Neurological Disease
P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y₁₂R ligand with a K_i value of 17.1 nM. P2Y12R ligand-1 labeled with [ ¹⁸F] can be used in studies of brain PET imaging .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .

HY-175014

LGT-1	PD-1/PD-L1 Biochemical Assay Reagents	Cancer
LGT-1 is a PD-L1 ligand. LGT-1 labeled with ¹⁸F has an excellent specific uptake in B16-F10 tumor cells, and shows a high tumor uptake but a low liver uptake with good stability in B16-F10 tumor-bearing mice model. LGT-1 can be used as a radiotracer for PET imaging of PD-L1 expression in tumors .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-176834

3-Deoxy-3-fluoro-D-fructose	GLUT	Cancer
3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC₅₀s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers .

HY-173319

FAP-IN-5	FAP	Cancer
FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC₅₀ of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging .

HY-D2310

CXCR2 Probe 1	CXCR	Inflammation/Immunology
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-W755222

(S)-NODAGA-tris(t-Bu ester) (S)-NODAG	Biochemical Assay Reagents	Cancer
(S)-NODAGA-tris(t-Bu ester) ((S)-NODAG) is a NODAGA derivative. (S)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W591317

(R)-NODAGA-tris(t-Bu ester) (R)-NODAG	Radionuclide-Drug Conjugates (RDCs)	Cancer
(R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W724743

Losartan azide	Biochemical Assay Reagents	Cardiovascular Disease
Losartan azide is a click chemistry reagent containing an azide group and is a synthetic intermediate for the preparation of angiotensin AT1R-targeted renal PET imaging probe [18 F]fluoropyridine-losartan .

Cat. No.	Product Name	Type

HY-D2310

CXCR2 Probe 1	Fluorescent Dyes
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-D2343

PB0822	Fluorescent Dyes
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

Cat. No.	Product Name	Type

HY-141637

2-Deoxy-2-fluoro-D-glucose 2 Publications Verification 2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose	Biochemical Assay Reagents
2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-W250574

NOTA-bis(tBu)ester NOTA-bis(t-Butyl ester)	Biochemical Assay Reagents
NOTA-bis (tBu) ester is a derivative of NOTA (HY-134418). NOTA-bis (tBu) ester is radiolabeled with ⁶⁸Ga to form ZD2-( ⁶⁸Ga-NOTA) after conjugation with ZD2. ZD2-( ⁶⁸Ga-NOTA) can be used for PET imaging studies of pancreatic cancer .

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

Cat. No.	Product Name	Target	Research Area

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10136

IA9 2 Publications Verification human TREM-2 182-190	TREM receptor	Inflammation/Immunology
IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives Biochemical Assay Reagents	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-P2336A

CCZ01048 TFA 3 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P10136A

IA9 TFA 2 Publications Verification human TREM-2 182-190 TFA	TREM receptor	Inflammation/Immunology
IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11837

NECT-224	Biochemical Assay Reagents	Cancer
NECT-224 is a bifunctional chelator and a nectin-4 targeting peptide conjugate. NECT-224 can be used as a PET imaging agent when labeled with ⁶⁴Cu or ⁶⁸Ga .

HY-P11655

NOTA-TATE	Somatostatin Receptor	Neurological Disease
NOTA-TATE is a somatostatin receptor 2 (SSTR2) binder. NOTA-TATE binds to SSTR2 to enable targeting of SSTR2-positive tumour cells for PET imaging. NOTA-TATE can be used for the research of neuroendocrine tumours .

HY-P11718

cFLFLF	Formyl Peptide Receptor (FPR) Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with ⁶⁴Cu-CuCl₂ to form cFLFLFKPEG- ⁶⁴Cu. cFLFLFKPEG- ⁶⁴Cu is a neutrophil-specific PET imaging agent .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a HER2-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-P11576

Cyclic αvβ6	Integrin Radionuclide-Drug Conjugates (RDCs)	Cancer
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with ⁶⁸Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11845

DOTA-NT-20.3-IPBA	Radionuclide-Drug Conjugates (RDCs) Neurotensin Receptor	Cancer
DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [ ⁶⁸Ga]Ga .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for *PET* imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

HY-P11486

NOTA-RHAU18	Radionuclide-Drug Conjugates (RDCs) G-quadruplex DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [ ¹⁸F]AlF-NOTA-RHAU18. [ ¹⁸F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [ ¹⁸F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [ ¹⁸F]AlF-NOTA-RHAU18 can also be used in PET imaging studies .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992367

hIMB1636	TROP2	Cancer
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological *PET* imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

Cat. No.	Product Name	Chemical Structure

HY-141637S

2-Deoxy-2-fluoro-D-glucose-13C

2-Deoxy-2-fluoro-D-glucose- ¹³C is the ¹³C labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-141637S1

2-Deoxy-2-fluoro-D-glucose-13C6,d7

2-Deoxy-2-fluoro-D-glucose- ¹³C₆,d₇ is the ¹³C-labeled and deuterium labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

Cat. No.	Product Name		Classification

HY-180447

Tz-Ph-PEG4-NH-DOTA		Tetrazine
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: